Key points from article :
Juvenescence has secured $50m in a Series A financing round.
New funding was assigned for advancing the biotech’s AI programmes, rising licensing and partnership arrangements.
Insilico Medicine is specialising in the application of deep learning to drug discovery, ageing research.
NetraPharma is using artificial intelligence to improve clinical trial design.
Company signed deals with the Buck Institute for Research on Aging, a global leader in the field.
